medigraphic.com
ISSN 0187-5337 (Print)
Instituto Nacional de Perinatología

2009, Number 3

<< Back Next >>

Perinatol Reprod Hum 2009; 23 (3)

Use of steroids in the postnatal period

Hernández-Peláez G, Morales-Barquet D

Language: Spanish
References: 19
Page: 160-168
PDF size: 88.64 Kb.


ABSTRACT

The use of steroids in the postnatal period is one of the most common and controversial clinical practices in neonatology because they produce improvement in lung function as part of treatment and prevention of bronchopulmonary dysplasia in high-risk newborns. However, these drugs have significant adverse effects, mainly at neurological level, that are associated with children cerebral palsy and decreased cognitive function, so its use should be limited to cases of severe lung disease. Steroid use alternative to dexamethasone did not demonstrate a significant difference in oxygen requirements or a faster ventilatory withdrawal, so it has been proposed schemes using hydrocortisone as an alternative that has fewer side effects in the long-term neurodevelopment. Recent studies have proposed the use of inhaled steroids as a treatment alternative with lower systemic effects.


REFERENCES

  1. Baud O. Postnatal steroid treatment and brain development. Arch Dis Child Fetal Neonatal Ed 2004; 89: F: 96-F100.

  2. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in ther 1990. Early Hum Dev 1999; 53(3): 193-218.

  3. Grier D, Halliday L. Management of Bronchopulmonary dysplasia in infants, guidelines for corticosteroid use. Drugs 2005; 65(1): 15-29.

  4. Stark RA. Risks and benefits of postnatal corticosteroids. Pharmacology review. Neo Reviews 2005; 6(2): e 99-e103.

  5. Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC et al. Growth and developmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007; 120(1): 40-8.

  6. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114(6): 1649-57.

  7. Truffert P, Empana JP, Bréart G, Saugstad OD, Goelz R, et al. Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe: the EURAIL survey. Acta Paediatr 2003; 92: 948-951.

  8. Halliday HL, Ehrenkraz RA, Doyle LW. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; CD 001146.

  9. Halliday HL, Ehrenkraz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; CD 001144.

  10. Halliday HL, Ehrenkraz RA. Delayed (> 3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; CD001145.

  11. Cogo EP, Simonato M, Mariatiffiki G et al. Dexamethasone therapy in preterm infants developing bronchopulmonary dysplasia: Effect on pulmonary surfactant disaturated-phosphatidylcholine kinetics. Pediatric Research 2008; 63(4): 433-437.

  12. Ballabh P, Sinm M, Kumari J, Krauss AN, Jain A et al. Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. Arch Dis Child Fetal Neonatal Ed 2004; 89: F76-F83.

  13. Peltoniemi OM, Kari A, Heinonen K, Saarela T, Andersson S et al. 209 randomized, controlled trial on early low-dose hydrocortisone treatment for prevention of bronchopulmonary dysplasia (BPD). International Pediatric Research Foundation: 2004; 56 (3): 499.

  14. Yeh TF, Lin YJ, Lin CH, Huang CC, Hsieh WS et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350: 1304-13.

  15. Van der Heide-Jalving M, Kamphuis PJ, Van der Laan MJ, Wiegant VM. Short-and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr 2003; 92: 827-835.

  16. Banks AB. Postnatal dexamethasone for bronchopulmonary dysplasia: A systematic review and meta-analysis of 20 years of clinical trials. Neo Reviews 2002; 3(2): e 24-234.

  17. Doyle LW. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006; 117(1): 75-83.

  18. Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon BL et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999; 340(13): 1005-10.

  19. Kovacs LB, Davis M, Faucher D, Papageorgiou A. Efficacy of early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. International Pediatric Research Foundation 1996, 39 (4) Supplement 2, 337.




2020     |     www.medigraphic.com